Lilly’s orforglipron outperforms oral semaglutide in Phase 3 diabetes trial EP News Bureau Jun 9, 2026 Results from the ACHIEVE programme show A1C reduction and weight loss outcomes for orforglipron across three Phase 3 trials
Eli Lilly reports positive Phase 3 results for orforglipron in type 2 diabetes trials EP News Bureau Oct 20, 2025 Eli Lilly highlights findings from two late-stage trials demonstrating orforglipron’s effectiveness in improving blood sugar…
Lilly’s orforglipron and other key catalysts can reshape drug landscape in Q3 2025: GlobalData EP News Bureau Jul 14, 2025 Eli Lilly’s clinical data with orforglipron in patients with diabetes supports the drug’s potential as an obesity treatment, as…
